StreetInsider.com News Articles

SeaStar Medical CMO named 2026 Combat Nephrology Award recipient

Wed, 14 Oct 2026 08:37:12 -0400

SeaStar Medical Holding Corporation (Nasdaq: ICU) announced that its Chief Medical Officer, Col. (Ret.) Kevin Chung, MD, has been named the 2026 recipient of the Combat Nephrology Award at the Update in Critical Care Nephrology meeting in Madrid, Spain, held October 14–15, 2026.

The Combat Nephrology Award recognizes clinicians, researchers, and military medical officers who have made contributions to renal support in trauma and combat casualty environments. Dr. Chung succeeds Professor Claudio Ronco, MD, of the International Renal Research Institute of Vicenza and Università di Padova, who received the 2025 award.

"During the over two decades of caring for critically ill combat

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

Wed, 14 Oct 2026 08:37:00 -0400

Award recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support

Keynote presentation and award ceremony to occur at Update in Critical Care Nephrology 2026

DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that Chief Medical Officer Col. (Ret.) Kevin Chung, MD, MACP, FCCM, has been recognized as the 2026 recipient of

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

Wed, 14 Oct 2026 08:37:00 -0400

Award recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support

Keynote presentation and award ceremony to occur at Update in Critical Care Nephrology 2026

Form D SeaStar Medical Holding

Thu, 08 Oct 2026 12:52:00 -0400

si-local-file:///var/storage/secattach/20261008/27166060.html

FDA grants SeaStar Medical breakthrough device status for sepsis therapy

Wed, 07 Oct 2026 08:17:13 -0400

SeaStar Medical Holding Corporation (Nasdaq: ICU) announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic condition.

This marks the seventh Breakthrough Device Designation the SCD therapy has received across a range of indications. The FDA grants this designation when a device has the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions, and is intended to accelerate development, assessment, and review for approval.

Sepsis affects an estimated 1.7 million U.S. adults annually and

FDA grants SeaStar Medical breakthrough device status for sepsis therapy

Wed, 07 Oct 2026 08:17:13 -0400

Sepsis affects an estimated 1.7 million U.S. adults annually and

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

Wed, 07 Oct 2026 08:16:00 -0400

Potentially accelerates development, assessment, and review for approval by FDA

Sepsis impacts about 1.7 million U.S. adults annually and
contributes to nearly one in three in-hospital deaths

DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) therapy for the treatment of hyperinflammation in adult patients with sepsis

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

Wed, 07 Oct 2026 08:16:00 -0400

Potentially accelerates development, assessment, and review for approval by FDA

Sepsis impacts about 1.7 million U.S. adults annually and
contributes to nearly one in three in-hospital deaths

Form 8-K SeaStar Medical Holding For: Oct 05

Mon, 05 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261005/27149049.html

SeaStar Medical raises $3.3M through warrant exercise at reduced price

Mon, 05 Oct 2026 08:02:09 -0400

SeaStar Medical Holding Corporation (Nasdaq: ICU) announced it entered into definitive agreements on October 2, 2026, for the exercise of outstanding warrants covering 854,002 shares of common stock, generating approximately $3.3 million in gross proceeds before placement agent fees and other expenses.

The warrants, originally issued in June, July, and August 2025, carried exercise prices ranging from $6.38 to $7.62 per share. Under the new agreements, holders exercised the warrants at a reduced price of $3.866 per share.

In exchange for the immediate cash exercise, SeaStar Medical will issue new unregistered warrants to purchase up to 1,708,004 shares of common stock at

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

Mon, 05 Oct 2026 08:00:00 -0400

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026, for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 854,002 shares of SeaStar Medical’s common stock, originally issued in June 2025, July 2025 and August 2025 (collectively, the “Prior Warrants”), having exercise prices ranging from $6.38 to $7.62 per share, at a reduced exercise price of

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

Mon, 05 Oct 2026 08:00:00 -0400

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

Fri, 02 Oct 2026 09:43:00 -0400

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.

Presentation Details:

Title: Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

Fri, 02 Oct 2026 09:43:00 -0400

Presentation Details:

Title: Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

Thu, 01 Oct 2026 08:21:00 -0400

New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy

Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy

DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced that effective today, October 1, 2026, new ICD-10-PCS codes are available to enable administrative, billing, and statistical reporting for the use of SeaStar Medical’s

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

Thu, 01 Oct 2026 08:21:00 -0400

New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy

Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy

SeaStar Medical CMO to present at pediatric therapy conference

Tue, 29 Sep 2026 08:36:16 -0400

SeaStar Medical Holding Corporation (Nasdaq: ICU) announced that its Chief Medical Officer, Kevin Chung, M.D., will deliver a presentation at the 2026 Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS), hosted by Texas Children's Hospital in Houston, Texas, from October 6 to 8, 2026.

Dr. Chung is scheduled to speak during a session titled "The Future of Pediatric Extracorporeal Therapies Innovation, Emerging Technologies, and the Next Generation of Support" on October 6, 2026, from 8:30 a.m. to 10:00 a.m. CDT. His presentation will focus on lessons learned in medical device development, using the company's QUELIMMUNE therapy as a case example.

The same session

SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

Tue, 29 Sep 2026 08:36:00 -0400

Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI)

DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Chief Medical Officer, Kevin Chung, M.D., will deliver an invited talk at the 2026 PPETS conference, hosted by Texas Children’s Hospital in Houston, Texas, October 6 - 8, 2026.

The annual PPETS conference gathers leading

SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

Tue, 29 Sep 2026 08:36:00 -0400

Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI)

The annual PPETS conference gathers leading

SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

Thu, 24 Sep 2026 08:16:00 -0400

Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE® for critically ill pediatric patients with acute kidney injury (AKI)

SeaStar Medical’s SCD development pipeline of indications holds promise for multiple additional indications

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that H. David Humes, M.D., is being awarded this year’s Distinguished University Innovator of the

SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

Thu, 24 Sep 2026 08:16:00 -0400

SeaStar Medical’s SCD development pipeline of indications holds promise for multiple additional indications

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:35:00 -0400

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City.

The SeaStar Medical presentation will be available on September 11, 2026, at 7:00 am Eastern Time and can be accessed by visiting the Events &

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:35:00 -0400

The SeaStar Medical presentation will be available on September 11, 2026, at 7:00 am Eastern Time and can be accessed by visiting the Events &

Form 4 SeaStar Medical Holding For: Aug 18 Filed by: Messinger Michael

Wed, 19 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260819/26950348.html

Form 4 SeaStar Medical Holding For: Aug 18 Filed by: Messinger Michael

Wed, 19 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260819/26950348.html